modelA06AC06
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Methylcellulose | |
| ATC code: | A06AC06 | route: | oral |
| compartments: | 1 | |
| dosage: | 2000 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | L/h |
| other parameters in model implementation | ||
Methylcellulose is a semi-synthetic, inert, hydrophilic compound derived from cellulose. It is used primarily as a bulk-forming laxative to treat constipation and to promote regular bowel movements. Methylcellulose is currently approved and in widespread clinical use as an over-the-counter oral laxative. It is also used as a food additive and in pharmaceutical formulations as a thickener or emulsifier.
Pharmacokinetics
No relevant pharmacokinetic (PK) studies in humans reporting systemic absorption or standard PK parameters (such as volume of distribution, clearance, or bioavailability), since methylcellulose is recognized as not systemically absorbed in the gastrointestinal (GI) tract when administered orally as a laxative. All parameters estimated based on its clinical pharmacology and non-absorption.
References
Kim, TH, et al., & Shin, BS (2017). Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation. Molecular pharmaceutics 14(1) 53–65. DOI:10.1021/acs.molpharmaceut.6b00677 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27809538
Sova, P, et al., & Chládek, J (2011). A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV). Cancer chemotherapy and pharmacology 67(6) 1247–1256. DOI:10.1007/s00280-010-1411-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20697713
Anup, N, et al., & Kumar Tekade, R (2024). Plasmonic laser-responsive BioDissolve 3D-printed graphene@cisplatin-implant for prevention of post-surgical relapse of oral cancer. International journal of pharmaceutics 657 124123–None. DOI:10.1016/j.ijpharm.2024.124123 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38621618
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)